

Cite this: *RSC Adv.*, 2017, 7, 27384Received 17th March 2017
Accepted 17th May 2017

DOI: 10.1039/c7ra03152a

rsc.li/rsc-advances

Recent progress in ergot alkaloid research†

Jing-Jing Chen, Meng-Yao Han, Ting Gong, Jin-Ling Yang and Ping Zhu *

Ergot alkaloids are a class of indole derivatives produced by the genera of Ascomycota including *Claviceps*, *Aspergillus*, *Penicillium*, and *Epichloë*. Many natural and semi-synthetic ergot alkaloids exhibit valuable pharmacological activities and have been widely used in the therapy of human CNS disorders. Owing to the development of genome sequencing technology, the gene clusters involved in the biosynthesis of ergot alkaloids have been identified from these fungi. In this review, we briefly introduce the pharmacological activities and possible mechanisms of action of some ergot alkaloids. Then we summarize the recent progress in the functional characterization of the key genes and gene clusters involved in the biosynthetic pathways of ergot alkaloids from different genera. Particularly, we summarize and discuss the constructions of ergot alkaloid biosynthetic pathways in different heterologous hosts and the optimization strategies performed on the recombinant strains, which provide references for producing ergot alkaloids and the derivatives in cell factories by synthetic biology in the future.

1. Introduction

Ergot alkaloids are a class of indole derivatives having biological and medicinal activities. Over the past decades, the pharmacological activities of these compounds have been extensively studied.¹ In the Middle Ages, ergot alkaloids were thought to be natural toxins with an impact on human health.² It is well known that the main producers of ergot alkaloids are members of the genus *Claviceps*, which belongs to Ascomycotina in taxonomy. As a parasitic fungus, *Claviceps* can grow on grass or grain and the ingestion of the infected grass or grain by humans or animals led to the breakout of severe epidemics.^{3,4} In 1850, a clearer understanding of ergot poisoning was provided when the French scientist Tulasne comprehensively elucidated the life cycle of *Claviceps*. The Swiss biochemist Stoll first isolated ergotamine in 1918, and the Swiss psychiatrist Maier found it to be effective for the treatment of migraines in 1926, marking the beginning of the modern study of ergot alkaloids.^{5,6} In recent years, other genera of Ascomycota including *Aspergillus*⁷ and *Penicillium*,⁸ even *Epichloë* have also been proven to produce ergot alkaloids.

All ergot alkaloids have an indole-derived tetracyclic ring structure (ergoline) in common, wherein the A and B rings are from L-tryptophan, and the C and D rings are from the

cyclization of dimethylallyl pyrophosphate (DMAPP) and L-tryptophan. As shown in Fig. 1, based on their structures, ergot alkaloids are usually divided into three classes.^{1,9,10} Clavine-type alkaloids (ergoclavines), in which chanoclavine-I aldehyde is the common structural scaffold, are mainly produced by *Aspergillus* and *Penicillium*. Some ergoclavines such as chanoclavine-I, agroclavine and elymoclavine are also the intermediates of ergoamides and ergopeptines. Ergoamides, including D-lysergic acid amide, D-lysergic acid α -hydroxyethylamide and ergometrine, are the simpler derivatives of D-lysergic acid. Ergopeptines, the complicated derivatives of D-lysergic acid, are the largest and most diverse class in ergot alkaloids. D-Lysergic acid derivatives are mainly produced by the genus *Claviceps*, some of them are produced by *Epichloë*.^{8,11–13} Most of the D-lysergic acid derivatives are bioactive, and have been widely used in the therapy of human CNS disorders. The detailed classification and structures of ergot alkaloids have been recently summarized elsewhere.¹ The NMR spectrums of some bioactive ergot alkaloids have been identified (Tables S1–S3†). Here, we briefly introduce the pharmacological activities and clinical applications of some ergot alkaloids and highlights the recent progress in the identification of the catalytic enzymes involved in the biosynthetic pathways of ergot alkaloids. The future perspective of the ergot alkaloids production in cell factories is also discussed.

2. Pharmaceutic activities and clinical applications of some ergot alkaloids

Fumigaclavine C, a clavine-type alkaloid, is a promising molecule for the treatment of inflammatory bowel diseases and

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Biosynthesis of Natural Products of National Health and Family Planning Commission, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China. E-mail: zhuping@imm.ac.cn; Fax: +86-10-63017757; Tel: +86-10-63165197

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra03152a




Fig. 1 Structures of some ergot alkaloids in which the compounds with clinical applications are marked with *.

atherosclerosis.^{14–19} Ergometrine (also known as ergonovine, an amide derivative of D-lysergic acid) has the function of causing contractions of the uterus and can be used to treat bleeding

after childbirth.² Many natural ergopeptines and semi-synthetic ergot alkaloids exhibit remarkable pharmaceutical activities due to their interactions with receptors in the central nervous



system, and are of value in the treatment of neurological disorders (Fig. 1). For example, ergotamine and its derivative dihydroergotamine are used for treatment of acute migraine attacks.^{20–23} Hydergine (trade name), a mixture of the methanesulfonate salts of four dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, α -dihydroergocryptine and β -dihydroergocryptine), has been used to treat dementia and age-related cognitive impairment (such as Alzheimer's disease).^{24–26} α -Dihydroergocryptine (the trade name: Vasobral) is effective as monotherapy in the early stages of Parkinson's disease and for the treatment of low blood pressure.^{27,28} Bromocryptine synthesized by the bromination of α -ergocryptin using *N*-bromosuccinimide is used for the treatment of Parkinson's disease and hyperprolactinaemia.^{29,30} Nicergoline is a derivative of *D*-lysergic acid and is used in the treatment of dementia and vascular disorders such as cerebral thrombosis.^{31–33} Another *D*-lysergic acid derivative, Cabergoline, is frequently used as a first-line agent in the treatment of prolactinomas, since it has a more convenient dosing schedule than Bromocryptine.^{34–38} Pergolide is also a dopamine receptor agonist used in some countries for the treatment of Parkinson's disease, although it was withdrawn from the U.S. market for human use in March 2007 due to serious valvular damage.^{39,40} These clinical applications are summarized in Table 1.

3. Biosynthetic pathways of ergot alkaloids

3.1 Common biosynthetic pathway towards chanoclavine-I-aldehyde

The primary biosynthetic pathway of ergot alkaloids is shown in Fig. 2, which led to the formation of chanoclavine-I aldehyde.

The first step of the whole pathway is the condensation reaction of *L*-tryptophan and DMAPP, in which DMAPP as the product of mevalonate pathway provides the isoprene group for this reaction. The enzyme responsible for this step is dimethylallyltryptophan (DMAT) synthase (DMATS), which is the rate-limiting enzyme in the synthesis of ergoline and is regulated

positively by tryptophan and negatively by the intermediates agroclavine and elymoclavine.⁴¹ The coding genes of DMATS in *C. purpurea* and *C. fusiformis* have been cloned and named *cpd1* and *dmaW*, respectively, but the corresponding sequences of encoded proteins are quite different.^{42–44} DMATS is a homodimer with a molecular weight of 105 kDa.^{42,44} It was reported that *fgaPT2* in *Aspergillus fumigatus* is the homologous gene of *dmaW*, which was supported by the result that no ergot alkaloids could be detected in the *fgaPT2* knockout strain while the production ability of the mutant could be restored when *fgaPT2* was re-transformed.⁴⁵ Similar phenomena were confirmed in *C. fusiformis* and *Epichloë* species.⁴⁶ Unsöld *et al.* cloned *fgaPT2* from *A. fumigatus* and expressed it in *Saccharomyces cerevisiae*, and the results showed that *fgaPT2* is a soluble dimer with a molecular weight of 104 kDa.⁴⁷ Sequence analysis showed that there was no assumed binding site of the enzyme for isoprene pyrophosphate, however, it could still use *L*-tryptophan and DMAPP as substrates to form DMAT. In this reaction, metal ions such as magnesium and calcium ions can increase the reaction rate.⁴⁸ Sixteen new members of the DMATS family from other species have also been cloned, expressed and identified in recent years. Most of these enzymes only accept DMAPP as the donor of the isoprene group, and the prenylation often occurs at the C4 position of the substrates.⁴⁹ The existence of a dimethylallyl cation intermediate in the aromatic prenyltransferase reaction could explain the mechanism of DMATS, which involves a discrete dimethylallyl cation intermediate or an associative mechanism in which the indole ring directly displaces diphosphate.^{50–52} The phylogenetic analysis indicated that *dmaW* of *A. fumigatus* has the same origin as those from *clavicipitaceous* fungi.⁵³ The relationships of authentic *dmaW* genes also suggest that they originated from multiple gene duplications with subsequent losses of original or duplicate versions in some lineages.

The second reaction is the methylation of 4-DMAT, while the methyl group of *S*-adenosine methionine (SAM) is transferred to the amino nitrogen of DMAT under the catalysis of *N*-methyltransferase, generating *N*-methyl-dimethylallyltryptophan (Me-

Table 1 Summary of some bioactive ergot alkaloids and their clinical applications

Name	Pharmaceutic activity	Indications	Reference
Fumigaclavine C	Inhibiting NLRP3 inflammasome activation; attenuating TNF α via the TLR4-NF κ B signaling transduction pathway	Inflammatory bowel diseases and atherosclerosis	14–19
Ergometrine	Promoting contraction of the uterus	Bleeding after childbirth	2
Ergotamine	5-HT receptor agonist	Acute migraine attack	22 and 23
Dihydroergotamine	5-HT receptor agonist	Acute migraine attack	20–23
α -Dihydroergocryptine	α -Adrenergic antagonist and dopamine agonist	Parkinson's disease and low blood pressure	27 and 28
Hydergine ^a	Interacting with D ₁ - and D ₂ -subtypes of dopamine receptors	Dementia and Alzheimer disease	24–26
Bromocryptine	Dopamine agonist	Parkinson's disease and hyperprolactinaemia	29 and 30
Nicergoline	α -1A adrenergic receptor antagonist	Vascular disorders and dementia	31–33
Cabergoline	Inhibiting the secretion of prolactin from the pituitary; dopamine agonist	Prolactinomas and Parkinson's disease	34–38
Pergolide	Dopamine agonist	Parkinson's disease	39 and 40

^a Mixture of dihydroergocristine, dihydroergocornine, α -dihydroergocryptine, β -dihydroergocryptine.






Fig. 2 The common biosynthetic pathway of ergot alkaloids in different fungal species. (DmaW, EasF, EasE, EasC and EasD are the enzymes responsible for the synthesis of chanoclavine-I-aldehyde in *C. purpurea*; the homologous enzymes in *A. fumigatus* are FgaPT2, FgaMT, FgaOx1, FgaCat and FgaDH, respectively).

DMAT). The enzymes responsible for this reaction in *C. purpurea* and *A. fumigatus* are encoded by *easF* and *fgaMT*, respectively, and both of them are SAM-dependent methyltransferases. In addition, Rigbers *et al.* successfully expressed *fgaMT* in *Escherichia coli*, and the results suggest that recombinant FgaMT with a molecular weight of 38.1 kDa transfers DMAT into Me-DMAT in the presence of SAM *in vitro* without the participation of metal ions.⁵⁴

The third reaction is the transformation of Me-DMAT to chanoclavine-I. Tudzynski *et al.* speculated that this process comprised at least three reactions, including cyclization, decarboxylation and hydroxylation.⁵⁵ First, the bond linking C8 and C9 in Me-DMAT is desaturated, while the proton of C17 is lost, resulting in the formation of a diene. Subsequently, the rotation around the C8–C9 bond and the oxidation of C8–C7 occur to give an epoxide intermediate. Following this, the decarboxylation reaction of this intermediate occurs, accompanied by the formation of a new bond between C5 and C10. Ring opening of the epoxide occurs by proton attack, with the shift of the double bond between C9 and C10 to C8 and C9. In recent years, some laboratories have conducted detailed research on the enzyme responsible for the formation of chanoclavine-I in *C. purpurea* and *A. fumigatus* by gene knockout experiments. Lorenz *et al.* found that chanoclavine-I and other downstream products could not be detected in the *easE* (previously referred to as *ccsA*) deleted strain of *C. purpurea* P1, while the amount of 4-DMAT was increased. Meanwhile, the complementation of the $\Delta easE$ mutant with its respective gene fragments resulted in the mutant indistinguishable from the wild-type strain in its capacity for ergot alkaloid biosynthesis. All of the above results suggest that EasE plays a distinct role in the formation of chanoclavine-I.⁵⁵ The *easE* gene contains two exons plus one intron and is 1503 bp in length, and the encoded protein is 483 amino acids. EasE has a high similarity with redox enzymes from other fungi that produce ergot alkaloids, such as the homologous protein EasE in *C. fusiformis* (*E* values for e^{-160}), EasE in *Neotyphodium lolii*, the genus being merged into *Epichloë* in 2014⁵⁶ (*E* values for e^{-118}) and FgaOx1 in *A. fumigatus* (*E* values for e^{-96}). The domain located in the 14–161

amino acids of the protein is determined to be the flavin adenine dinucleotide (FAD)-binding domain by sequence analysis, suggesting that EasE might work in a FAD-dependent manner.⁵⁵ A similar conclusion was revealed by Goetz *et al.*, who found that no chanoclavine-I could be detected in the *fgaOx1* (the homologous gene of *easE* in *C. purpurea*) mutant of *A. fumigatus*.⁵⁷ More importantly, the gene *fgaCat* in *A. fumigatus* (the homologous gene of *easC* in *C. purpurea*) is essential for the production of ergot alkaloids. The *fgaCat* deletion strain could not produce chanoclavine-I and other products such as festuclavine and fumigaclavine A, B and C, instead it accumulated the intermediate Me-DMAT.⁵⁷ Thus, the results suggest that FgaCat and FgaOx1 are both required for the transformation of Me-DMAT to chanoclavine-I, and function as catalase and oxidoreductase, respectively. FgaCat might decompose the hydrogen peroxide produced by FgaOx1 in the oxidation reaction.⁵⁷

The next reaction is the generation of chanoclavine-I-aldehyde by the redox of chanoclavine-I under the action of oxidoreductase. Wallwey *et al.* determined that the enzyme (designated as FgaDH) for *A. fumigatus* is composed of 261 amino acids with a molecular weight of approximately 27.8 kDa and contains conserved motifs of short-chain dehydrogenase/reductases (SDRs). The oxidation and dehydrogenation of chanoclavine-I were catalyzed by FgaDH *in vitro* in the presence of NAD^+ .⁵⁸ The homologous enzyme (designated as EasD) of FgaDH has been discovered in *Claviceps*.¹ In addition, the genome sequence analysis of *Arthrodermataceae* revealed the presence of a gene cluster consisting of five genes with high similarity to those involved in the biosynthesis of chanoclavine-I aldehyde in *A. fumigatus* and *C. purpurea*. The gene ARB_04646 in *Arthroderma benhamiae* was expressed in *E. coli*, and the results showed that the encoded enzyme catalyzed the oxidation of chanoclavine-I in the presence of NAD^+ , resulting in the formation of chanoclavine-I aldehyde.⁵⁹ Thus, this gene as the homologous gene of *easD* and *fgaDH* also functioned as the oxidoreductase. At the present time, the four reactions described above constitute the common biosynthetic pathway of ergot alkaloids in different fungal species (Fig. 2).



3.2 Biosynthetic pathway of ergoclavines

Chanoclavine-I-aldehyde is proposed as a branch point *via* festuclavine or pyroclavine to clavine-type alkaloids in *Aspergillus* and *Penicillium*, and *via* agroclavine to ergoamides and ergopeptines in *Claviceps*.⁶⁰ The disruption of *fgaOx3* in *A. fumigatus*, a gene predicted to encode a flavin-dependent oxidoreductase of the old yellow enzyme class, led to the accumulation of the upstream product chanoclavine-I-aldehyde. The complementation of the *fgaOx3* mutant with a wild-type allele restored the original profile of ergot alkaloids. The results suggest that FgaOx3 is required for the incorporation of chanoclavine-I-aldehyde into more complex ergot alkaloids.⁶¹ In addition, FgaOx3 reduces the double bond between C8 and C9 of chanoclavine-I aldehyde, and the reduction facilitates an intramolecular reaction between the aldehyde and the amine moieties to allow the formation of festuclavine, which was recently confirmed by the crystal structure resolution of the FMN-loaded FgaOx3.^{60,62,63} Wallwey *et al.* reported that the oxidoreductase FgaFS in *A. fumigatus* reduced the cyclic iminium product formed by FgaOx3 to produce festuclavine.⁶⁴ In an *in vitro* reaction system, festuclavine was formed when chanoclavine-I aldehyde was incubated with the recombinant FgaOx3 and FgaFS simultaneously or as a tandem-reaction with FgaOx3 before FgaFS in the presence of NADH (Fig. 3).⁶⁴ In *Penicillium*, chanoclavine-I-aldehyde is usually converted to pyroclavine. It was reported that FgaOx3 and FgaFS from *P. commune* catalyzed the formation of pyroclavine and a small amount of festuclavine (Fig. 3). More importantly, a detailed inspection of the HPLC chromatogram of the incubation mixture with FgaOx3 and FgaFS from *A. fumigatus* also revealed the presence of a minor product pyroclavine.⁶⁵ The two products

both can be produced by using different combinations of FgaOx3 and FgaFS from *A. fumigatus* and *P. commune*,⁶⁵ and the ratio of pyroclavine to festuclavine was controlled by the reduction of an imine intermediate catalyzed by FgaFS (Fig. 3).

On the other hand, chanoclavine-I-aldehyde is usually converted to agroclavine in *C. purpurea* (Fig. 4). The structural difference between festuclavine and agroclavine is whether there is a double bond between the C8 and C9 positions. The homologs of FgaOx3 (designated as EasA) and FgaFS (designated as EasG) in *C. purpurea* comprise 290 and 369 amino acids, respectively, with molecular weights of 31.9 and 41.5 kDa.⁶⁶ Cheng proposed that EasA controlled the conversion of chanoclavine-I aldehyde to festuclavine or agroclavine. In the presence of NADPH, festuclavine was observed when FgaOx3_{Af} and FgaFS_{Af} were incubated with chanoclavine-I aldehyde, which is consistent with Wallwey's results mentioned above.^{64,67} In contrast, agroclavine was also yielded when chanoclavine-I aldehyde was incubated with EasA_{NI} from *Epichloë lolii* (the homolog of FgaOx3 in *A. fumigatus*) and FgaFS_{Af} (Fig. 3) simultaneously. The results indicated that FgaOx3_{Af} acted as a reductase and EasA_{NI} acted as an isomerase. The mutational analysis suggests that Tyr to Phe mutation of EasA is responsible for this switch in activity from a reductase (as found in *A. fumigatus*) to an isomerase (as found in *N. lolii*).⁶⁷ In addition, it was reported that in the presence of reduced glutathione (GSH), chanoclavine-I aldehyde was converted to agroclavine by the recombinant EasA and EasG from *C. purpurea*. Most surprisingly, they found that only EasG itself could catalyze the conversion of chanoclavine-I aldehyde to agroclavine in the presence of reduced GSH and NADPH *in vitro*. GSH and NADPH could be replaced by NADH and other thiol




Fig. 3 *In vitro* reaction from chanoclavine-I-aldehyde to festuclavine and/or pyroclavine and agroclavine catalyzed by the recombinant EasA and EasG from different strains in varied combinations.






Fig. 4 The biosynthetic pathways of clavine-type alkaloids or D-lysergic acid from the branch point chanoclavine-I aldehyde in different species. The end products in different species are underlined.

compounds, such as 2-mercaptoethanol and dithiothreitol, indicating that EasG is sufficient for the conversion of chanoclavine-I aldehyde to agroclavine without EasA *in vitro* (Fig. 3).⁶⁶ In this reaction, EasG possibly serves as an oxidoreductase to reduce the Schiff base.

In *A. fumigatus*, festuclavine was transformed to the final product fumigaclavine C by some enzymes.⁶⁸ Compared with festuclavine, a prenyl group and acetyl groups are present at the C2 and C9 of fumigaclavine C, respectively. Thus, the formation of fumigaclavine C is proposed to occur through hydroxylation, acetylation and prenylation. It is reported that only festuclavine was produced in the *fgaP450-2* (also referred as *easM*) deletion mutant. Complementation with *fgaP450-2* gene restored the ability of the fungus to produce the downstream compounds.⁶⁹ The results suggest that festuclavine is converted to (8S,9S)-fumigaclavine B by the hydroxylase FgaP450-2 (EasM). The acetyl group provided by acetyl coenzyme A is further transferred to the C8 of (8S,9S)-fumigaclavine B by acetyltransferase FgaAT, generating (8S,9S)-fumigaclavine A, and then (8S,9S)-fumigaclavine A is prenylated by prenyltransferase with DMAPP as the prenyl group donor, to form the final product (8S,9S)-fumigaclavine C.⁷⁰ The prenyltransferase gene *fgaPT1* has been identified in *A. fumigatus* AF293. FgaPT1 was demonstrated to cause the formation of a C–C bond between the C-3 of the prenyl group from DMAPP and the C-2 of the indole nucleus and therefore to function as a reverse prenyltransferase.^{70,71} The

enzyme shares high sequence similarity with DMATS which functions as a prenyltransferase in the first pathway-specific step of the ergot alkaloid biosynthesis in different fungi, such as *C. purpurea*, *C. fusiformis*, *Neothyphodium coenophialum*, *Balansia obtecta*, and *A. fumigatus* AF293. Thus, it can be concluded that FgaPT1 is evolved from a regular prenyltransferase in fungi.

Cycloclavine contains an unusual cyclopropyl moiety, and this alkaloid has recently been found in *A. japonicus* (Fig. 4).⁷² The analysis of the *A. japonicus* genome revealed an EAS gene cluster, in which most of the genes are homologous to those involved in the biosynthesis of festuclavine or agroclavine in other filamentous fungi. Upon the incubation of chanoclavine-I aldehyde with cofactors and enzymes heterologously expressed from *E. coli* (EasA_{Aj}, EasG_{Aj}) and yeast (EasH_{Aj}), the formation of cycloclavine and festuclavine was detected. EasH acted as a hydroxylase in this reaction. Most interestingly, the manipulation of the EasA_{Aj}/EasG_{Aj}/EasH_{Aj} ratio controlled the contents of cycloclavine and festuclavine.⁷²

In *Penicillium*, the final product is (8R,9S)-fumigaclavine A, resulted from a subsequent reaction *via* the intermediates 8R-pyroclavine and (8R,9S)-fumigaclavine B (Fig. 4).⁸ Compared with the structures of the clavine-type final products in *Aspergillus* and *Penicillium*, the differences are the prenyl group present or absent at the C2 position and the stereochemistry of the C8. Fumigaclavine A is the final product in *Penicillium* due



to the lack of a specific prenyltransferase FgaPT1 that exists in *A. fumigatus*.⁷¹

In summary, the early stages of the ergot alkaloid pathway (up to chanoclavine-I aldehyde) are shared by different fungi, including *Claviceps*, *Aspergillus* and *Penicillium*, whereas the later stages of the pathway are different (Fig. 4).

3.3 Biosynthetic pathway of D-lysergic acid derivatives

3.3.1 Biosynthesis of D-lysergic acid. In *C. purpurea*, agroclavine is further oxidized to paspalic acid via elymoclavine by P450 monooxygenase in the presence of NADPH and oxygen, and paspalic acid can be spontaneously isomerized to D-lysergic acid. The P450 monooxygenase CloA responsible for the conversion of elymoclavine to paspalic acid has been identified. D-Lysergic acid and its derivatives could not be detected in the *cloA* deletion strain, but the production of agroclavine and elymoclavine was increased. The retransformation of the mutant with the intact *cloA* gene could restore the ergopeptine synthesis.⁷³ In addition, by expressing CloA along with the isomerase form of EasA of *Epichloë* sp. Lp1 in an *easA* knockout mutant of *A. fumigatus*, D-lysergic acid was produced in the resultant strain.⁷⁴ These results suggest that CloA catalyzes the conversion of agroclavine to D-lysergic acid, which bridges the biosynthesis of clavines and D-lysergic acid derivatives. The synthetic process of D-lysergic acid in *C. purpurea* is summarized in Fig. 4.

3.3.2 Biosynthesis of ergoamides and ergopeptines. The ergoclavines are the final products in the *Aspergillus* and *Penicillium* species. However, in the *Claviceps* species, the carbonyl group of D-lysergic acid is attached to an amino alcohol or a bicyclic three-peptide chain via an amide bond to form relatively simple derivatives such as ergometrine and complex derivatives (ergopeptines) such as ergotamine.⁷⁵ The differences between the various ergopeptines are mainly reflected in the first and second amino acids of the tripeptide chain, which are usually non-polar, while the third amino acid is always proline. Many studies showed that the biosynthetic processes of ergoamides and ergopeptines are assembled by D-lysergyl peptide synthetases (LPSSs), which belong to the family of non-ribosomal peptide synthetases (NRPSs). The enzymes contain one or more modules, and a typical module is composed of at least three essential C-A-T domains, which mediate the substrate selection and activation (adenylation domain, A domain), the substrate binding and shuttling among the active sites (thiolation domain, T domain, or a small peptidyl carrier protein, PCP), and peptide bond formation between the acyl-S-PCP intermediates of two adjacent modules (condensation domain, C domain). The termination module also contains an additional thioesterase (Te) domain, responsible for the product release, either by hydrolysis or by cyclization (also called Cyc domain), to generate either cyclic or cyclic-branched molecules.^{1,10,76,77}

Four *lps* genes have been identified from the *C. purpurea* P1 strain, which has been supported by the genome sequencing of *C. purpurea* 20.1.^{12,13,75,78} Correia *et al.* identified the structure and function of LPSB (formerly known as LPS2) by

transcriptional analysis, gene disruption and heterologous expression. LPSB is a mono-modular NRPS containing three domains in the order of A-T-C, with a molecular weight of 140 kDa, and it is encoded by *lpsB*. LPSB is responsible for the D-lysergic acid activation and incorporation into the D-lysergic acid amide or ergopeptine backbone. Ergopeptines were undetectable in *lpsB* gene deletion strain, whereas the accumulation of D-lysergic acid was clearly detected.¹² LPSA is a triple-modular NRPS catalyzing ergopeptide formation. Two LPSA variants were found, namely, LPSA1 (370 kDa, formerly known as LPS1) and LPSA2 (370 kDa, formerly known as LPS4), encoded by *lpsA1* and *lpsA2*, respectively.⁷⁹ The phylogenetic analysis revealed that the first and third AT-didomains in the module 1 and module 3 of the LPSA-type enzymes were likely evolved from a common ancestor, or that the module 3 was derived from the module 1 by gene duplication. In contrast, the AT-didomain of module 2 was phylogenetically distant from those of the modules 1 and 3.⁶⁹ Most interestingly, the phylogenetic tree also exhibited that both the C domains of the modules 1 and 3 were clustered into the same clade, whereas the C domain from the module 2 was attributed to another clade. All of the above results suggest that the modules of LPSSs in the *Claviceps* species are organized as A-T-C units but not canonical C-A-T units (Fig. 5).⁷⁵ The ergopeptine biosynthesis is initiated by the binding of D-lysergic acid to the T domain of LPSB as a thioester followed by the transfer of the thioester to the triple-modular LPSA1 or LPSA2, where three successive condensations into the D-lysergyl mono-, di-, and tripeptide thioester intermediates occur, with the final release of the end product D-lysergyl tripeptide lactam (ergopeptam).^{12,75} In this process, the LPSB and LPSA are probably in the form of an LPSB/LPSA complex. Haarmann *et al.* reported that the mutant lacking the *lpsA1* gene was incapable of producing ergotamine but still able to produce α -ergocryptine, suggesting that LPSA1 is involved in the synthesis of ergotamine in the *C. purpurea* P1 strain and that the three A domains of LPSA1 are responsible for the activation of alanine, phenylalanine, and proline, respectively.⁷⁸ This result also implies that LPSA2 is responsible for the biosynthesis of α -ergocryptine.^{78,79} However, this speculation is questionable, because it cannot explain how one strain can sometimes produce more than two ergopeptides. Besides the variation in the modules of the LPSSs, the promiscuity of the substrate amino acids for LPSSs should be considered. Therefore, the accurate relationships between the different ergopeptines and LPSA1 or LPSA2, *i.e.*, the product specificities of LPSA1 and LPSA2, need to be further investigated.

After releasing from the corresponding LPS, ergopeptam is oxidized to form ergopeptine under the action of a P450 monooxygenase named EasH1, with a molecular weight of 35 kDa. The only difference between the ergopeptam and the corresponding ergopeptine is that the former lacks a cyclol group between the α -C of the first amino acid and the carbonyl group of the third amino acid proline. Havemann and Keller carried out a detailed study of this process.⁸⁰ The results showed that EasH1 acted as an oxygenase or a hydroxylase dependent on the presence of Fe²⁺/2-ketoglutarate (Fig. 5). EasH1 introduced






Fig. 5 Ergopeptide biosynthesis in *Claviceps*. Note: R1 and R2 represent different groups.

a hydroxyl group into the D-lysergyl tripeptide lactam at the α -C of the aminoacyl residue followed by the spontaneous condensation with the terminal lactam carbonyl group. The sequence analysis revealed that EasH1 belonged to the wide and diverse family of phytanoyl coenzyme A hydroxylases.⁸⁰

The *C. purpurea* Ecc93 strain, an ergocristine producer, can also produce a smaller amount of ergometrine. Ortel and Keller discovered the enzyme (designated as LPSC or LPS3) responsible for ergometrine synthesis.⁷⁵ LPSC is a monomodular NRPS with a molecular weight of 180 kDa and contains not only an A domain, T domain and C domain but also a C-terminal reductase domain (Red/R domain). The R domain acts as a reductase with homology to the C-terminal Red-domains of other NRPS members. This R domain is capable of catalyzing the electron reduction of the respective carrier protein-bound thioester, thereby releasing the former intermediate as an alcohol-type product.^{75,81} As shown in Fig. 6, D-lysergic acid is attached to alanine under the functions of LPSB and LPSC, which are responsible for the D-lysergic acid and alanine activation, respectively. Finally, ergometrine is released in the presence of NADPH. It was speculated that the C domain of LPSB is responsible for the amide bond formation between the T domain-bound D-lysergic acid and alanine. However, according to the blasting result LPSC also harbors a C domain whose function is uncertain. Crocacinins are natural antifungal compounds produced by myxobacteria. These compounds are most likely derived from an NRPS/PKS hybrid biosynthetic

pathway. Its biosynthesis involves an unusual hydrolytic release domain similar to the C domain of LPSC.⁸¹ Consequently, the C domain of LPSC together with its R domain may catalyze the release of the final product but not catalyze the amide bond formation.

The *lpsC* genes were also cloned from the *C. purpurea* D1 and P1 strains, and the two nucleotide sequences share up to 90% identities with that of the Ecc93 strain. However, the D1 and P1 strains mainly produced ergopeptines and only minimal ergometrine. The RT-PCR analysis showed that the *lpsC* expressions occurred at the transcriptional level in all strains, but the LPSC proteins in the D1 and P1 strains were not detected by the antibody prepared with the partial LPSC fragment from the *C. purpurea* Ecc93 strain, which may be the reason why ergometrine was not detected in the two strains.⁷⁵

C. paspali mainly produces simple lysergic acid derivatives such as lysergic acid α -hydroxyethylamide and ergometrine. The enzymes EasO and EasP in *C. paspali* are speculated to be involved in the biosynthesis of lysergic acid α -hydroxyethylamide (Fig. 6). The sequence analysis indicated that *easO* encodes a flavin-binding monooxygenase (EasO) that may oxidize the α -carbon of the alanine-derived residue in the ergometrine precursor attached to the LpsB/LpsC complex, while *easP* encodes an α/β hydrolase-fold enzyme (EasP), which could be involved in the subsequent hydrolysis to release lysergic acid α -hydroxyethylamide.^{13,82}






Fig. 6 Ergoamide biosynthesis in *Claviceps*.

4. Gene cluster for ergot alkaloid biosynthesis

In fungi and bacteria, the genes involved in the biosynthesis of the corresponding secondary metabolites are generally located on the chromosome with a continuous and clustered manner. This facilitates the identification of the genes responsible for the biosynthesis of certain compounds. Tudzynski *et al.* explored the adjacent gene sequences of *dmaW* using chromosome walking and found an ergot alkaloid synthesis (EAS) gene cluster located at the 3' end of *dmaW* in the *C. purpurea* P1 strain.⁸³ Then, a total of 11 genes were determined in which *easA* and *lpsA1* were located on the left and right flanks of *dmaW*, respectively. Subsequently, Harrmann *et al.* discovered another two new NPRS members (*lpsC* and *lpsA2*). The length of the gene cluster was eventually confirmed to be 68.5 kb, containing a total of 14 genes (Fig. 7),⁷⁹ whose functions have been characterized. The core genes involved in the two clusters of *C. purpurea* P1 (ergotamine producer) and *C. purpurea* ECC93 (ergocristine producer) are highly conserved. Yet the NRPS genes are various, which may contribute the various ergot alkaloid spectra among the two strains except for the promiscuity of the substrate amino acids for the LPSS. Lorenz *et al.* screened the positive clone containing fragment contigs from the *C. fusiformis* SD58 plasmid library by using the cDNA of *dmaW* as a probe.⁴³ After sequencing these contigs, they found a sequence with a size of 19.6 kb containing 9 homologous genes of the *C. purpurea* EAS gene cluster (Fig. 7).⁸⁴ This gene cluster in *C. fusiformis* does not contain the homologous genes of *lpsC*, *lpsA1* and *lpsA2* of *C. purpurea*. The *CloA* and *LPSB* in *C. fusiformis* have lost their functions although the coding genes (*cloA* and *lpsB*) were expressed normally. Consequently, only ergoclavines such as agroclavine and elymoclavine are produced by *C. fusiformis*.⁸⁴ The gene cluster of *C. hirtella* has also been investigated. This strain mainly produces ergoclavines together with a small amount of ergometrine (3–8% of total ergot alkaloids).⁸⁵ The analysis of its EAS gene cluster indicated that no homologous genes of *lpsA1* and *lpsA2* but only genes of *lpsB* and *lpsC* existed in it.⁸⁶

Recently, the EAS gene cluster with a length of 27 kb from *A. fumigatus* Af293 has also been identified by the DNA blast with

the gene sequence of *dmaW* from *C. purpurea*. This cluster is located on chromosome 2 and contains 11 genes 45 in which seven homologous genes with 46–66% identities were found in both *A. fumigatus* Af293 and *C. purpurea*. As shown in Fig. 7, the homologous genes of *A. fumigatus*, *P. commune* and *C. purpurea* are involved in the early stage of the ergot alkaloid biosynthetic pathway (up to agroclavine). Other than ergopeptines being produced in *Claviceps*, fumigaclavines are the final products of *A. fumigatus*⁷ and *P. commune*.⁸ The specific gene *fgaPT1* located 10 kb away from *fgaPT2* in the genome of *A. fumigatus* Af293 was found to catalyze the last reaction step in fumigaclavine C biosynthesis.⁷¹ In contrast, no *fgaPT1* gene was found in the EAS gene cluster of *P. commune*, leading to the production of fumigaclavine A which lacks the prenyl group at the C2 position. In addition, the EAS cluster of *A. japonicus* has been found to be 16.8 kb in length and contain 8 genes (Fig. 7), among which seven (*dmaW*, *easF*, *easE*, *easC*, *easD*, *easA*, *easG*) are homologous to those previously found in other filamentous fungi, leading to the formation of festuclavine. The *easH* in *A. japonicus* is highly identical to the *easH1* in *C. purpurea*, leading to the formation of cycloclavine which contains a cyclopropyl moiety.⁷²

The *Epichloë* EAS clusters are also available in the NCBI database, such as those of *Epichloë festucae* Fl1, *E. glyceriae* E277, *E. typhina* E5819 and *E. festucae* E2368. However, the distances between some genes in the EAS cluster are quite long. For example, in *E. festucae* E2368 *easH* is almost 25 kb far away from *dmaW*, and *easD* is almost 15 kb far away from *lpsA*. Due to the lack of *lpsC*, the aforementioned strains mainly produce ergovaline but not ergometrine or lysergic acid α-hydroxyethylamide. Another advance is the discovery of the EAS clusters in *Neotyphodium* (*Epichloë*) species. The principal alkaloids produced by *E. gansuense* E818 are simpler lysergyl amides, including high levels of ergometrine and low levels of lysergic acid α-hydroxyethylamide.¹³ Its EAS cluster is arranged similarly to that of *Claviceps*, although it is separated into two parts. The lack of *lpsA1* and *lpsA2* makes the strain as a producer of ergometrine. Like *C. paspali*, the *easO* and *easP* present in the EAS cluster of *E. gansuense* E818 make it produce lysergic acid α-hydroxyethylamide. The EAS gene cluster of *E. coenophialum* E4163 contains 11 genes. The arrangement order and physical distance of genes are extremely similar to those of *Epichloë*.






Fig. 7 Ergot alkaloid synthesis (EAS) gene clusters in *Claviceps*, *Aspergillus*, *Penicillium*, and *Epichloë*. Black boxes represent the homologous genes between different species.

Therefore, ergovaline is speculated to be its product, and its pharmacological activity needs to be evaluated. In addition, *E. lolii* Lp19 mainly produces ergovaline. However, the reported EAS cluster of *E. lolii* Lp19 in NCBI database only contains 6 genes.⁸⁷ Compared with the EAS clusters of other *Epichloë* species, it is possible that the other genes (*dmaW*, *cloA*, *easC*, *easD* and *lpsA*) also exist in the EAS cluster of *N. lolii* Lp19 but have not been found due to the long distance between *dmaW* and *easH*. Overall, the biosynthetic pathways of ergot alkaloids in different species are summarized in Fig. S1.†

5. Production of ergot alkaloids by synthetic biology or metabolic engineering

In recent years, the applications of synthetic biological techniques provide probabilities for mass production of natural pharmaceutical products or their precursors in cell factories, which leads to a new era of biotechnology. Some progress have also been made in the construction of the EAS pathways in different heterologous hosts, such as *Aspergillus nidulans*, *A. fumigatus* and *S. cerevisiae*, to produce some intermediates or novel ergot alkaloids derivatives.^{72,74,88–90}

The first attempt for the construction of the ergot alkaloid biosynthetic pathway was taken in the *A. nidulans* host. *A. nidulans* as a model fungus has a very close genetic relationship with *A. fumigatus*, but it does not produce ergot alkaloids due to the absence of the EAS gene cluster, which makes it a suitable host for observing the effectiveness of the engineered EAS pathway. The

partial EAS gene cluster of *A. fumigatus*, which harbored *dmaW*, *easF*, *easC* and *easE*, was introduced into the *A. nidulans* host, and with the intrinsic DMAPP and L-tryptophan as the substrates, the engineered mold acquired the ability to produce chanoclavine-I, although the yield was only 3 ng mm⁻² of the culture surface area (Fig. 8).⁹⁰ If the gene cluster only harbored *dmaW*, *easF* and *easC*, the recombinant strain produced ergotryptamine instead of chanoclavine-I. The role of ergotryptamine as a pathway intermediate or byproduct was tested by feeding ergotryptamine to *A. fumigatus easC* knockout (ko) and *A. fumigatus easE* ko strains. Although both the strains contain downstream pathway enzymes, they failed to turn over ergotryptamine, indicating that ergotryptamine is not the precursor of chanoclavine-I.⁸⁹

The similar work has also been done in the *S. cerevisiae* host (Fig. 8).^{72,88} The four EAS genes of *dmaW* (*A. japonicus* origin), *easF* (*A. fumigatus* origin), *easC* (*A. japonicus* origin) and *easE* (*A. japonicus* origin) were combined in the host and the engineered yeast produced little amount of chanoclavine-I.⁸⁸ The chanoclavine-I amount was increased to 0.75 mg L⁻¹ when the recombinant strain overexpressed the molecular chaperones PD11 and ERO1, which may improve the folding of EasE.⁸⁸ The pathway was further stretched to cycloclavine after *easD* (*A. japonicus* origin), *easA* (*A. japonicus* origin), *easH* (*A. japonicus* origin) and *easG* (*A. japonicus* origin) were introduced into the engineered yeast. By increasing the copy number of *dmaW*, *easC*, *easD*, *easH*, *easG*, *pdi1* and *fad1*, the cycloclavine yield was further increased to 529 mg L⁻¹.⁷² However, when *easH* was not involved in the aforementioned pathway, the recombinant strain produced another product festuclavine (Fig. 8). It is worth mentioning that cycloclavine is the first relatively more






Fig. 8 The constructed ergot alkaloid biosynthetic pathways in different hosts.

complicated ergot alkaloid successfully produced by the engineered yeast (Fig. 8).

Robinson and Panaccione⁷⁴ even introduced *easA* (functioned as an isomerase) from *Epichloë* species into *A. fumigatus* $\Delta easA$ (also referred as *fgaOx3*) mutant, which harbored the intrinsic EAS pathway from DMAPP to chanoclavine-I aldehyde, and instead of the intermediate product festuclavine, agroclavine together with its oxidation product setoclavine was yielded, and the former is also one of the key EAS intermediates

found in *Claviceps* species (Fig. 4). Then the *cloA* gene from *Epichloë* species was added to the pathway, and the engineered mold acquired the ability to produce D-lysergic acid (Fig. 8).⁷⁴

6. Prospective

Studies on the biosynthetic pathway of ergot alkaloids have achieved great progress. So far, most of the related enzymes involved in the biosynthetic pathway of ergot alkaloids are



clearly elucidated. These breakthroughs provide a better understanding of the biosynthesis of ergot alkaloids, and make it possible to improve the yields of ergot alkaloids through the enzyme regulation. At present, the production of ergot alkaloids with various pharmacological activities is mainly based on the liquid fermentation of the selected *Claviceps* strains. However, these selected *Claviceps* strains, especially high producers, are generally unstable and apt to degeneration during the cultivation and preservation process. Moreover, the components of the alkaloids are usually complex, which leads to the increase in the cost of isolation and purification. Therefore, the alternative approaches need to be developed. The booming synthetic biology may solve these problems, which is based on the reconstruction of the EAS pathway in an engineered microbial cell factory. Currently, the partial biosynthetic pathways of ergot alkaloids have been constructed in the cell factories and the corresponding intermediates are produced. However, the yields of these intermediates are quite low. Furthermore, these intermediates are much simple and far from the final products on the biosynthetic pathway. More efforts are required to improve the productivity, which include further optimizing the EAS pathway, genome editing, improving the enzyme activities and fitness in the engineered host, and increasing the precursor supply. There is still a long way to realize the efficient and large-scale productions of ergot alkaloids or their novel derivatives in the cell factories by the metabolic engineering.

Acknowledgements

This work was supported by the Fundamental Research Funds for the Institute of Materia Medica (Grant No. 2015CX07), Fundamental Research Funds for the Central Universities (Grant No. 2016ZX350018), National Natural Science Foundation of China (Grant No. 81603002) and CAMS Innovation Fund for Medical Sciences (CIFMS) (Grant No. 2016-I2M-2-002).

References

- 1 C. Wallwey and S.-M. Li, *Nat. Prod. Rep.*, 2011, **28**, 496–510.
- 2 C. De Costa, *Lancet*, 2002, **359**, 1768–1770.
- 3 A. N. de Groot, P. W. van Dongen, T. B. Vree, Y. A. Hekster and J. van Rosmalen, *Drugs*, 1998, **56**, 523–535.
- 4 T. Haarmann, Y. Rolke, S. Giesbert and P. Tudzynski, *Mol. Plant Pathol.*, 2009, **10**, 563–577.
- 5 M. Lee, *J. Roy. Coll. Phys. Edinb.*, 2009, **39**, 365–369.
- 6 M. Lee, *J. Roy. Coll. Phys. Edinb.*, 2009, **39**, 179–184.
- 7 H. M. Ge, Z. G. Yu, J. Zhang, J. H. Wu and R. X. Tan, *J. Nat. Prod.*, 2009, **72**, 753–755.
- 8 N. Vinokurova, S. Ozerskaya, B. Baskunov and M. Arinbasarov, *Microbiology*, 2003, **72**, 149–151.
- 9 M. Flieger, M. Wurst and R. Shelby, *Folia Microbiol.*, 1997, **42**, 3–30.
- 10 H. Hulvová, P. Galuszka, J. Frébortová and I. Frébort, *Biotechnol. Adv.*, 2013, **31**, 79–89.
- 11 N. Flieger, P. Sedmera, J. Vokoun, Z. Řeháček, J. Stuchlík, Z. Malinka, L. Cvak and P. Harazim, *J. Nat. Prod.*, 1984, **47**, 970–976.
- 12 T. Correia, N. Grammel, I. Ortel, U. Keller and P. Tudzynski, *Chem. Biol.*, 2003, **10**, 1281–1292.
- 13 C. L. Schardl, C. A. Young, U. Hesse, S. G. Amyotte, K. Andreeva, P. J. Calie, D. J. Fleetwood, D. C. Haws, N. Moore and B. Oeser, *PLoS Genet.*, 2013, **9**, e1003323.
- 14 R. H. Du, E. G. Li, Y. Cao, Y. C. Song and R. X. Tan, *Life Sci.*, 2011, **89**, 235–240.
- 15 R. H. Du, S. Y. Qin, L. S. Shi, Z. Q. Zhou, X. Y. Zhu, J. Liu, R. X. Tan and W. Cao, *Atherosclerosis*, 2014, **234**, 120–128.
- 16 W. Guo, S. Hu, F. Shao, R. Ren, W. Liu, W. Zhang, X. Wang, R. Tan, Q. Xu and Y. Sun, *J. Pharmacol. Sci.*, 2015, **129**, 101–106.
- 17 Y.-X. Li, S. Himaya, P. Dewapriya, C. Zhang and S.-K. Kim, *Mar. Drugs*, 2013, **11**, 5063–5086.
- 18 X.-F. Wu, M.-J. Fei, R.-G. Shu, R.-X. Tan and Q. Xu, *Int. Immunopharmacol.*, 2005, **5**, 1543–1553.
- 19 Y. Zhao, J. Liu, J. Wang, L. Wang, H. Yin, R. Tan and Q. Xu, *J. Pharm. Pharmacol.*, 2004, **56**, 775–782.
- 20 G. Jourdan, P. Verwaerde, A. Pathak, M. A. Tran, J. L. Montastruc and J. M. Senard, *Fundam. Clin. Pharmacol.*, 2007, **21**, 45–53.
- 21 J. R. Saper and S. Silberstein, *Headache*, 2006, **46**, S171–S181.
- 22 S. D. Silberstein and D. C. McCrory, *Headache*, 2003, **43**, 144–166.
- 23 S. D. Silberstein, *Headache*, 1996, **37**, S15–S25.
- 24 R. McDonald, *Pharmacopsychiatry*, 1979, **12**, 407–422.
- 25 I. Setnikar, K. Schmid, L. C. Rovati, B. Vens-Cappell, D. Mazur and I. Kozak, *Arzneimittelforschung*, 2001, **51**, 2–6.
- 26 R. Markstein, *Eur. J. Pharmacol.*, 1982, **86**, 145–155.
- 27 B. Bergamasco, L. Frattola, A. Muratorio, F. Piccoli, F. Mailland and L. Parnetti, *Acta Neurol. Scand.*, 2000, **101**, 372–380.
- 28 L. T. Williams, D. Mullikin and R. Lefkowitz, *J. Biol. Chem.*, 1976, **251**, 6915–6923.
- 29 M. J. Bannon, A. A. Grace, B. S. Bunney and R. H. Roth, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 1980, **312**, 37–41.
- 30 J. McMurtry, N. Kazama and B. Wexler, *Exp. Biol. Med.*, 1979, **161**, 186–188.
- 31 A. Battaglia, G. Bruni, A. Ardia, G. Sacchetti, A. Baroni, R. Cisbani, P. Bovi, G. Roncolato, M. Dotto and G. Frascella, *J. Am. Geriatr. Soc.*, 1989, **37**, 295–302.
- 32 B. Saletu, E. Paulus, L. Linzmayer, P. Anderer, H. V. Semlitsch, J. Grünberger, L. Wicke, A. Neuhold and I. Podreka, *Psychopharmacology*, 1995, **117**, 385–395.
- 33 B. Winblad, M. Fioravanti, T. Dolezal, I. Logina, I. G. Milanov, D. C. Popescu and A. Solomon, *Clin. Drug Invest.*, 2008, **28**, 533–552.
- 34 F. Bracco, A. Battaglia, C. Chouza, E. Dupont, O. Gershanik, J. F. M. Masso and J.-L. Montastruc, *CNS Drugs*, 2004, **18**, 733–746.
- 35 M. P. Curran and C. M. Perry, *Drugs*, 2004, **64**, 2125–2141.
- 36 U. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, J. M. Masso, J. Montastruc and C. Marsden, *Drugs*, 1998, **55**, 23–30.
- 37 J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts,



- P. Petrossians and P. Coremans, *J. Clin. Endocrinol. Metab.*, 1999, **84**, 2518–2522.
- 38 A. Colao, A. Di Sarno, M. L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, R. Volpe, F. Di Salle, S. Cirillo and L. Annunziato, *J. Clin. Endocrinol. Metab.*, 2000, **85**, 2247–2252.
- 39 G. Van Camp, A. Flamez, B. Cosyns, C. Weytjens, L. Muyldermans, M. Van Zandijcke, J. De Sutter, P. Santens, P. Decoodt and C. Moerman, *Lancet*, 2004, **363**, 1179–1183.
- 40 M. Goldstein, A. Lieberman, J. Y. Lew, T. Asano, M. R. Rosenfeld and M. H. Makman, *Proc. Natl. Acad. Sci. U. S. A.*, 1980, **77**, 3725–3728.
- 41 L.-J. Cheng, J. E. Robbers and H. G. Floss, *J. Nat. Prod.*, 1980, **43**, 329–339.
- 42 J. C. Gebler and C. D. Poulter, *Arch. Biochem. Biophys.*, 1992, **296**, 308–313.
- 43 H.-F. Tsai, H. Wang, J. C. Gebler, C. D. Poulter and C. L. Schardl, *Biochem. Biophys. Res. Commun.*, 1995, **216**, 119–125.
- 44 C. Arntz and P. Tudzynski, *Curr. Genet.*, 1997, **31**, 357–360.
- 45 C. M. Coyle and D. G. Panaccione, *Appl. Environ. Microbiol.*, 2005, **71**, 3112–3118.
- 46 J. Wang, C. Machado, D. G. Panaccione, H.-F. Tsai and C. L. Schardl, *Fungal Genet. Biol.*, 2004, **41**, 189–198.
- 47 I. A. Unsöld and S.-M. Li, *Microbiology*, 2005, **151**, 1499–1505.
- 48 E. Kranen, N. Steffan, R. Maas, S. M. Li and J. Jose, *ChemCatChem*, 2011, **3**, 1200–1207.
- 49 N. Steffan, I. A. Unsöld and S. M. Li, *ChemBioChem*, 2007, **8**, 1298–1307.
- 50 L. Y. Luk and M. E. Tanner, *J. Am. Chem. Soc.*, 2009, **131**, 13932–13933.
- 51 U. Metzger, C. Schall, G. Zocher, I. Unsöld, E. Stec, S.-M. Li, L. Heide and T. Stehle, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 14309–14314.
- 52 N. Steffan and S.-M. Li, *Archives of microbiology*, 2009, **191**, 461–466.
- 53 M. Liu, D. G. Panaccione and C. L. Schardl, *Evol. Bioinf. Online*, 2009, **5**, 15.
- 54 O. Rigbers and S.-M. Li, *J. Biol. Chem.*, 2008, **283**, 26859–26868.
- 55 N. Lorenz, J. Olšovská, M. Šulc and P. Tudzynski, *Appl. Environ. Microbiol.*, 2010, **76**, 1822–1830.
- 56 A. Leuchtmann, C. W. Bacon, C. L. Schardl, J. F. White Jr and M. Tadych, *Mycologia*, 2014, **106**, 202–215.
- 57 K. E. Goetz, C. M. Coyle, J. Z. Cheng, S. E. O'Connor and D. G. Panaccione, *Curr. Genet.*, 2011, **57**, 201–211.
- 58 C. Wallwey, M. Matuschek and S.-M. Li, *Arch. Microbiol.*, 2010, **192**, 127–134.
- 59 C. Wallwey, C. Heddergott, X. Xie, A. A. Brakhage and S.-M. Li, *Microbiology*, 2012, **158**, 1634–1644.
- 60 J. Z. Cheng, C. M. Coyle, D. G. Panaccione and S. E. O'Connor, *J. Am. Chem. Soc.*, 2010, **132**, 1776–1777.
- 61 C. M. Coyle, J. Z. Cheng, S. E. O'Connor and D. G. Panaccione, *Appl. Environ. Microbiol.*, 2010, **76**, 3898–3903.
- 62 X. Xie, C. Wallwey, M. Matuschek, K. Steinbach and S. M. Li, *Magn. Reson. Chem.*, 2011, **49**, 678–681.
- 63 A. S. Chilton, A. L. Ellis and A. L. Lamb, *Acta Crystallogr., Sect. F: Struct. Biol. Commun.*, 2014, **70**, 1328–1332.
- 64 C. Wallwey, M. Matuschek, X.-L. Xie and S.-M. Li, *Org. Biomol. Chem.*, 2010, **8**, 3500–3508.
- 65 M. Matuschek, C. Wallwey, B. Wollinsky, X. Xie and S.-M. Li, *RSC Adv.*, 2012, **2**, 3662–3669.
- 66 M. Matuschek, C. Wallwey, X. Xie and S.-M. Li, *Org. Biomol. Chem.*, 2011, **9**, 4328–4335.
- 67 J. Z. Cheng, C. M. Coyle, D. G. Panaccione and S. E. O'Connor, *J. Am. Chem. Soc.*, 2010, **132**, 12835–12837.
- 68 D. G. Panaccione and C. M. Coyle, *Appl. Environ. Microbiol.*, 2005, **71**, 3106–3111.
- 69 Y. Bilovol and D. G. Panaccione, *Curr. Genet.*, 2016, **62**, 853–860.
- 70 S.-M. Li and I. A. Unsöld, *Planta Med.*, 2006, **72**, 1117–1120.
- 71 I. A. Unsöld and S. M. Li, *ChemBioChem*, 2006, **7**, 158–164.
- 72 D. Jakubczyk, L. Caputi, A. Hatsch, C. A. Nielsen, M. Diefenbacher, J. Klein, A. Molt, H. Schroder, J. Z. Cheng, M. Naesby and S. E. O'Connor, *Angew. Chem.*, 2015, **54**, 5117–5121.
- 73 T. Haarmann, I. Ortel, P. Tudzynski and U. Keller, *ChemBioChem*, 2006, **7**, 645–652.
- 74 S. L. Robinson and D. G. Panaccione, *Appl. Environ. Microbiol.*, 2014, **80**, 6465–6472.
- 75 I. Ortel and U. Keller, *J. Biol. Chem.*, 2009, **284**, 6650–6660.
- 76 M. A. Marahiel, *Nat. Prod. Rep.*, 2016, **33**, 136–140.
- 77 M. Z. Ansari, G. Yadav, R. S. Gokhale and D. Mohanty, *Nucleic Acids Res.*, 2004, **32**, W405–W413.
- 78 T. Haarmann, N. Lorenz and P. Tudzynski, *Fungal Genet. Biol.*, 2008, **45**, 35–44.
- 79 T. Haarmann, C. Machado, Y. Lübke, T. Correia, C. L. Schardl, D. G. Panaccione and P. Tudzynski, *Phytochemistry*, 2005, **66**, 1312–1320.
- 80 J. Havemann, D. Vogel, B. Loll and U. Keller, *Chem. Biol.*, 2014, **21**, 146–155.
- 81 S. Müller, S. Rachid, T. Hoffmann, F. Surup, C. Volz, N. Zaburannyi and R. Müller, *Chem. Biol.*, 2014, **21**, 855–865.
- 82 N. Castagnoli, K. Corbett, E. Chain and R. Thomas, *Biochem. J.*, 1970, **117**, 451–455.
- 83 P. Tudzynski, K. Hölter, T. Correia, C. Arntz, N. Grammel and U. Keller, *Mol. Gen. Genet.*, 1999, **261**, 133–141.
- 84 N. Lorenz, E. V. Wilson, C. Machado, C. L. Schardl and P. Tudzynski, *Appl. Environ. Microbiol.*, 2007, **73**, 7185–7191.
- 85 S. Pazoutová, M. Kolařík, G. Odvody, D. Frederickson, J. Olšovská and P. Man, *Fungal Divers.*, 2008, **95**, 95–111.
- 86 N. Lorenz, T. Haarmann, S. Pažoutová, M. Jung and P. Tudzynski, *Phytochemistry*, 2009, **70**, 1822–1832.
- 87 D. J. Fleetwood, B. Scott, G. A. Lane, A. Tanaka and R. D. Johnson, *Appl. Environ. Microbiol.*, 2007, **73**, 2571–2579.
- 88 C. A. Nielsen, C. Folly, A. Hatsch, A. Molt, H. Schröder, S. E. O'Connor and M. Naesby, *Microb. Cell Fact.*, 2014, **13**, 95.
- 89 K. L. Ryan, N. G. Akhmedov and D. G. Panaccione, *J. Agric. Food Chem.*, 2014, **63**, 61–67.
- 90 K. L. Ryan, C. T. Moore and D. G. Panaccione, *Toxins*, 2013, **5**, 445–455.

